With the success of Onpattro, an LNP formulation of siRNA used for the treatment of polyneuropathy caused by the hereditary transthyretin-mediated amyloidosis [27], and the mRNA vaccines developed by Moderna and Pfizer, both of which employ LNPs to deliver mRNA vaccine against COVID-19 [13], LNPs have overshadowed other RNA delivery systems and dominated this field of research. The gene discussed is TTR; the disease is polyneuropathy.